Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy TFF Pharmaceuticals stock

Own TFF Pharmaceuticals stock in just a few minutes.

TFF Pharmaceuticals, Inc is a biotechnology business based in the US. TFF Pharmaceuticals shares (TFFP) are listed on the NASDAQ and all prices are listed in US Dollars. TFF Pharmaceuticals employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in TFF Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TFFP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

TFF Pharmaceuticals share price

Use our graph to track the performance of TFFP stocks over time.

TFF Pharmaceuticals shares at a glance

Information last updated 2021-04-23.
52-week range$4.31 - $21.14
50-day moving average $14.04
200-day moving average $15.43
Wall St. target price$31.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.00

Buy TFF Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy TFF Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TFF Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -34.44%
Return on equity TTM -57.14%
Profit margin 0%
Book value N/A
Market capitalisation $291.4 million

TTM: trailing 12 months

Shorting TFF Pharmaceuticals shares

There are currently 438,531 TFF Pharmaceuticals shares held short by investors – that's known as TFF Pharmaceuticals's "short interest". This figure is 43.6% up from 305,330 last month.

There are a few different ways that this level of interest in shorting TFF Pharmaceuticals shares can be evaluated.

TFF Pharmaceuticals's "short interest ratio" (SIR)

TFF Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TFF Pharmaceuticals shares currently shorted divided by the average quantity of TFF Pharmaceuticals shares traded daily (recently around 425758.25242718). TFF Pharmaceuticals's SIR currently stands at 1.03. In other words for every 100,000 TFF Pharmaceuticals shares traded daily on the market, roughly 1030 shares are currently held short.

However TFF Pharmaceuticals's short interest can also be evaluated against the total number of TFF Pharmaceuticals shares, or, against the total number of tradable TFF Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TFF Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 TFF Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0221% of the tradable shares (for every 100,000 tradable TFF Pharmaceuticals shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TFF Pharmaceuticals.

Find out more about how you can short TFF Pharmaceuticals stock.

TFF Pharmaceuticals share dividends

We're not expecting TFF Pharmaceuticals to pay a dividend over the next 12 months.

TFF Pharmaceuticals overview

TFF Pharmaceuticals, Inc. , an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site